Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

X
Trial Profile

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IO 102 (Primary) ; IO-103 (Primary) ; Nivolumab (Primary) ; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jan 2023 Status changed from recruiting to discontinued.
    • 09 Nov 2022 According to an IO Biotech media release, data from this trial are being presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022).
    • 05 Oct 2022 According to an IO Biotech media release, update on this study will be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top